Investors toasted Biogen CEO Michel Vounatsos last June after the Food and Drug Administration approved the company's Alzheimer's monoclonal antibody, Aduhelm—the first treatment that has been shown to slow progression of the debilitating disease. It was expected to become a blockbuster in short order.
